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OBJECTIVE—We investigated the effects of 34 genetic risk
variants for hyperglycemia/type 2 diabetes on lipoprotein sub-
classes and particle composition in a large population-based
cohort.
RESEARCH DESIGN AND METHODS—The study included
6,580 nondiabetic Finnish men from the population-based Meta-
bolic Syndrome in Men (METSIM) study (aged 57 6 7 years; BMI
26.8 6 3.7 kg/m
2). Genotyping of 34 single nucleotide polymor-
phism (SNPs) for hyperglycemia/type 2 diabetes was performed.
Proton nuclear magnetic resonance spectroscopy was used to
measure particle concentrations of 14 lipoprotein subclasses and
their composition in native serum samples.
RESULTS—The glucose-increasing allele of rs780094 in GCKR
was signiﬁcantly associated with low concentrations of VLDL
particles (independently of their size) and small LDL and was
nominally associated with low concentrations of intermediate-
density lipoprotein, all LDL subclasses, and high concentrations
of very large and large HDL particles. The glucose-increasing
allele of rs174550 in FADS1 was signiﬁcantly associated with high
concentrations of very large and large HDL particles and nomi-
nally associated with low concentrations of all VLDL particles.
SNPs rs10923931 in NOTCH2 and rs757210 in HNF1B genes
showed nominal or signiﬁcant associations with several lipopro-
tein traits. The genetic risk score of 34 SNPs was not associated
with any of the lipoprotein subclasses.
CONCLUSIONS—Four of the 34 risk loci for type 2 diabetes or
hyperglycemia (GCKR, FADS1, NOTCH2, and HNF1B) were sig-
niﬁcantly associated with lipoprotein traits. A GCKR variant pre-
dominantly affected the concentration of VLDL, and the FADS1
variant affected very large and large HDL particles. Only a limited
number of risk loci for hyperglycemia/type 2 diabetes signiﬁ-
cantly affect lipoprotein metabolism. Diabetes 60:1608–1616,
2011
H
yperglycemia is closely related to lipid and lipo-
protein metabolism. Elevated levels of fasting
and 2-h plasma glucose or the presence of type
2 diabetes are associated with an increase in
total triglyceride (TG) concentrations, a decrease in HDL
cholesterol (1,2), and the formation of small, dense LDL
cholesterol particles (2). Several population-based studies
have shown that high levels of TG and low levels of HDL
cholesterol predict the development of type 2 diabetes
(3–6). Therefore, hyperglycemia and dyslipidemia are likely
to share similar pathophysiologic mechanisms, at least in
part. One of these mechanisms is insulin resistance, which
leads to hepatic overproduction of VLDL particles (espe-
cially large, TG-rich VLDL), attributable to an increased ﬂux
of free fatty acids from adipocytes into the liver, an in-
creased rate of apolipoprotein B synthesis and degradation
in the liver, and enhanced hepatic de novo lipogenesis by
hyperinsulinemia (7).
Genomewide association studies (GWAS) have identi-
ﬁed a number of gene variants reproducibly associated
with hyperglycemia or type 2 diabetes (8–10). Because hy-
perglycemia and dyslipidemia partly share similar patho-
physiologic mechanisms, the effects of hyperglycemia or
type 2 diabetes single nucleotide polymorphisms (SNPs)
on lipid and lipoprotein levels and composition are of great
interest. However, none of the previous studies has sys-
tematically examined this question using modern methods
to measure lipoprotein particle size and composition.
Compared with conventional methods, the measurement
of lipoprotein subclasses and particle composition pro-
vides more detailed information on the genes regulating
hyperglycemia or type 2 diabetes and their effects on lipid
metabolism.
We investigated the effects of the 34 risk loci for hyper-
glycemia or type 2 diabetes on lipoprotein subclasses and
particle composition. To this aim, we determined a total of
60 lipoprotein traits, including 14 lipoprotein subclasses and
their components, in 6,580 nondiabetic Finnish men.
RESEARCH DESIGN AND METHODS
Subjects. The study included 6,580 nondiabetic men from the population-based
Metabolic Syndrome in Men (METSIM) study who were a mean 6 SD age of
57 6 7 years. The study design has been described in detail elsewhere (11).
Glucose tolerance was evaluated according to the World Health Organization
criteria (12), based on glucose levels from a 2-h oral glucose-tolerance test
(OGTT) (75 g of glucose). Of these, 4,442 (67.5%) had normal glucose toler-
ance, 1,144 (17.4%) had isolated impaired fasting glucose, 582 (8.8%) had
isolated impaired glucose tolerance, and 412 (6.3%) had impaired fasting
glucose and impaired glucose tolerance. A total of 1,545 subjects (23.5%) were
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ORIGINAL ARTICLEreceiving statin treatment, and 16 (0.2%) were being treated with a ﬁbrate. The
study was approved by the ethics committee of the University of Kuopio and
Kuopio University Hospital, and was conducted in accordance with the Hel-
sinki Declaration.
Clinical measurements. Height and weight were measured to the nearest
0.5 cm and 0.1kg, respectively. BMI was calculated as weight (kilogram) divided
by height (meter) squared. Mean 6 SD BMI of the cohort was 26.8 6 3.7 kg/m
2.
Lipoprotein subclasses. Proton nuclear magnetic resonance (NMR) spec-
troscopy was used to measure lipid, lipoprotein subclass, and particle con-
centrations in native serum samples (13–15). NMR methods have been
described previously in detail (16,17). Serum concentrations were determined
for TG, total cholesterol (C), VLDL-TG, intermediate-density lipoprotein (IDL),
LDL, and HDL cholesterol. Total lipid and particle concentrations in 14 lipo-
protein subclasses were also measured. The measurements of these subclasses
have been validated against high-performance liquid chromatography (18). The
subclasses are as follows:
 chylomicrons (CM) and largest VLDL particles (CM/lar-VLDL), ﬁve different
VLDL subclasses: very large VLDL (vl-VLDL), large VLDL (l-VLDL), medium-
size VLDL (m-VLDL), small VLDL (s-VLDL), and very small VLDL (vs-VLDL);
 IDL;
 three LDL subclasses: large LDL (l-LDL), medium-size LDL (m-LDL), and
small LDL (s-LDL); and
 four HDL subclasses: very large HDL (vl-HDL), large HDL (l-HDL), medium-
size HDL (m-HDL), and small HDL (s-HDL).
The following components of the lipoprotein particles were measured: phos-
pholipids (PL), TG, cholesterol, free cholesterol (FC), and cholesterol ester
(CE). Average particle diameters and descriptive data for 60 traits are reported
in Table 1. Particle diameters of VLDL, LDL, and HDL were also measured.
Genotyping. Genotyping of 34 SNPs, comprising 20 risk SNPs for type 2 di-
abetes and 14 risk SNPs for fasting and 2-h glucose in an OGTT (8–10), was
performed using the TaqMan Allelic Discrimination Assay (Applied Bio-
systems, Carlsbad, CA) at the University of Eastern Finland (PPARG
rs1801282, KCNJ11 rs5219, TCF7L2 rs7903146, SLC30A8 rs13266634, HHEX
rs1111875, LOC387761 rs7480010, CDKN2B rs10811661, IGF2BP2 rs4402960,
CDKAL1 rs7754840, FTO rs9939609, HNF1B rs7501939, WFS1 rs10010131,
JAZF1 rs864745, CDC123 rs12779790, TSPAN8 rs7961581, THADA rs7578597,
ADAMTS9 rs4607103, NOTCH2 rs10923931, KCNQ1 rs2283228), or the iPlex
Gold SBE Assay (Sequenom, San Diego, CA) at the National Human Genome
Research Institute, National Institutes of Health (MTNR1B rs10830963,
ADRA2A rs10885122, FAM148A rs11071657, CRY2 rs11605924, ADCY5
rs11708067, SLC2A2 rs11920090, FADS1 rs174550, DGKB rs2191349, PROX1
rs340874, GCK rs4607517, G6PC2 rs560887, GLIS3 rs7034200, GCKR
rs780094, MADD rs7944584, GIPR rs10423928).
The TaqMangenotyping call rate was 100%, and the discordance rate was 0%
among 4.5% DNA samples genotyped in duplicate. The Sequenom iPlex call rate
was 90.2–96.9%, and the discordance rate was 0% among 4.2% DNA samples
genotyped in duplicate. All SNPs were consistent with Hardy-Weinberg equi-
librium at the signiﬁcance level corrected for multiple testing by Bonferroni
method (P = 0.0015). Descriptive data for individual SNPs are reported in
Supplementary Table 1.
Statistical analysis. Statistical analyses were conducted using SPSS 17
software (SPSS, Chicago, IL). All lipoprotein traits, BMI, and insulin sensitivity
index (Matsuda ISI) were log-transformed to correct for their skewed distri-
bution. Unstandardized effect sizes [B (SE)] per copy of the risk allele were
estimated by linear regression adjusted for covariates, using untransformed
dependent variables. Logarithmically transformed variables were used to
calculate P values. The values of lipid traits equal to 0 were excluded from all
analyses due to the need of log-transformation. The model included age, BMI,
statin treatment (yes/no), and smoking (yes/no) as covariates. Additional ad-
justment for serum TG levels or Matsuda ISI was performed for selected SNPs.
Hardy-Weinberg equilibrium was tested by the x
2 test. We primarily used a
conservative Bonferroni method to correct for multiple comparisons. A
P value of #2.3 3 10
25 was considered to be statistically signiﬁcant given
a total of 2,142 tests performed (63 traits 3 34 SNPs). However, the Bonferroni
correction for multiple testing might be too conservative because of high
correlations between the different lipoprotein traits and subclasses. Therefore,
we additionally used Benjamini-Hochberg-Yekutieli false discovery rate (FDR)
method (19) to correct for multiple comparisons under dependency assump-
tions. In these analyses the FDR-adjusted PFDR , 0.05 was considered sta-
tistically signiﬁcant. Pearson correlations were calculated to test the
association of lipoprotein traits with Matsuda ISI, calculated as [10,000/
= (fasting insulin 3 fasting glucose 3 mean insulin during OGTT 3 mean
glucose during OGTT)] (20). The genetic risk score (GRS) was calculated as a
sum of type 2 diabetes/hyperglycemia risk alleles in all 34 SNPs (GRS34)i n
20 type 2 diabetes risk SNPs (GRST2D) or in 17 hyperglycemia risk SNPs
(GRSGLU; details in Supplementary Table 6). Statistical power calculations
were performed using Bioconductor’s GeneticsDesign package version 1.16
(21). We had $80% power to detect changes in trait mean value from 1 to 28%
per copy of the risk allele at the signiﬁcance level of 0.05, depending on minor
allele frequency (Supplementary Fig. 1).
RESULTS
The P values and effect sizes for the associations between
34 SNPs and 60 lipoprotein traits are summarized in Fig. 1.
Two SNPs (GCKR rs780094 and FADS1 rs174550) were
signiﬁcantly associated with several lipoprotein traits after
adjustment for age, BMI, statin treatment, smoking, and
conservative Bonferroni correction for multiple testing
(P # 2.3 3 10
25). Two more SNPs (NOTCH2 rs10923931
and HNF1B rs7501939) showed signiﬁcant associations us-
ing a less conservative FDR correction for multiple testing
(PFDR , 0.05).
The type 2 diabetes risk (major) C allele of the intronic
SNP rs780094 at the GCKR gene was signiﬁcantly associated
with low particle concentrations of VLDL subclasses (from
vl- to s-VLDL, P =1 . 93 10
28 – 7.3 3 10
211), with effect sizes
from 24t o210% per allele (Fig. 2A, Supplementary Table
2). The C allele was also signiﬁcantly associated with low
concentrations of almost all components of (CM) and VLDL
( P L ,T G ,C ,F C ,a n dC E ) .F u r t h e r m o r e ,t h eC allele was
nominally associated with low particle concentrations of
CM/lar-VLDL (P =5 . 43 10
24), vs-VLDL (P =1 . 43 10
24),
and the l-LDL (P = 0.008), m-LDL (P =5 . 03 10
24), and s-
LDL (P =3 . 23 10
25) subclasses, and with high concen-
trations of vl-HDL (P = 0.031) and l-HDL (P =2 . 83 10
24)b u t
low concentration of s-HDL particles (P =8 . 43 10
25), as
well as with most of the components of these particles.
Associations for vs-VLDL, s-LDL, and s-HDL were statisti-
cally signiﬁcant when using the FDR correction (PFDR =
0.048, 0.015, and 0.030). This SNP tended to have larger and
more signiﬁcant effects on the TG components of most of
lipoprotein subclasses (CM, VLDL, IDL, and HDL) than on
other components. The C allele was also signiﬁcantly asso-
ciated with VLDL particle size (P =4 . 83 10
29), and nomi-
nally with LDL and HDL particle size (P =8 . 23 10
25 and 2.3
3 10
24). Almost all associations disappeared after additional
adjustment for serum levels of TGs, suggesting that they
were most likely secondary to the effects of rs780094 on TG
synthesis or metabolism.
The type 2 diabetes risk (major) T allele of the intronic
SNP rs174550 at the FADS1 gene was signiﬁcantly associ-
ated with high concentrations of vl-HDL (P =2 . 53 10
211)
and l-HDL (P =1 . 63 10
28) particles, with effect sizes of
6.7 and 4.8% per allele, and all their components (Fig. 2B,
Supplementary Table 3). The largest effect size (6.7% per
allele) was observed for the PL component of vl-HDL
particles (P = 2.6 3 10
28). Association with low concen-
tration of s-HDL particles was nominally signiﬁcant (P =
0.002). The T allele was also nominally associated with low
concentrations vl- to s-VLDL particles, and high concen-
trations of vs-VLDL and IDL particles (P = 2.8 3 10
24 to
0.032), as well as with components of VLDL and IDL par-
ticles. Rs174550 was also signiﬁcantly associated with
particle size of VLDL (P = 5.8 3 10
27) and HDL (P = 1.1 3
10
29), and nominally with LDL particle size (P = 0.001).
The associations with HDL subclasses and HDL particle
size were not considerably affected by additional adjust-
ment for TGs, suggesting that primary effect of the SNP
might be on HDL particles.
The type 2 diabetes risk (minor) T allele of the intronic
SNP rs7501939 at the HNF1B gene was nominally associated
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Descriptive statistics of 60 lipoprotein traits and their correlation with insulin sensitivity (Matsuda ISI)
Trait (mmol/L)
Particle diameter
(average, nm) n Mean (IQR)
Correlation with
Matsuda ISI
rP
CM/lar-VLDL-P $75.0 3,970 0.0001 (0.00003–0.00013) 20.321 5E-95
CM/lar-VLDL-PL 5,397 2.37 (1.19–3.54) 20.365 2E-168
CM/lar-VLDL-TG 6,177 14.7 (9.3–23.8) 20.409 4E-246
vl-VLDL-P 64.0 6,172 0.0007 (0.0005–0.0011) 20.396 5E-230
vl-VLDL-PL 6,155 11.1 (7.1–18.3) 20.399 3E-232
vl-VLDL-TG 6,368 46.1 (30.4–76.3) 20.417 2E-264
l-VLDL-P 53.6 6,490 0.005 (0.004–0.008) 20.428 4E-285
l-VLDL-PL 6,397 51.7 (37.2–86.0) 20.414 5E-262
l-VLDL-TG 6,534 182 (132–296) 20.450 ,4E-285
l-VLDL-C 6,428 61.6 (44.8–101.0) 20.391 9E-232
l-VLDL-FC 6,492 32.0 (23.3–52.5) 20.407 9E-256
l-VLDL-CE 6,312 30.1 (21.5–49.6) 20.358 3E-189
m-VLDL-P 44.5 6,580 0.018 (0.015–0.027) 20.441 ,4E-285
m-VLDL-PL 6,579 125 (108–183) 20.421 3E-279
m-VLDL-TG 6,577 335 (270–512) 20.447 ,4E-285
m-VLDL-C 6,580 174 (152–250) 20.383 3E-227
m-VLDL-FC 6,579 78.0 (66.6–115.5) 20.415 9E-271
m-VLDL-CE 6,580 95.8 (83.8–135.5) 20.338 6E-174
s-VLDL-P 36.8 6,580 0.034 (0.031–0.045) 20.377 9E-220
s-VLDL-PL 6,580 169 (155–213) 20.329 2E-164
s-VLDL-TG 6,580 287 (259–393) 20.415 3E-270
s-VLDL-C 6,580 298 (262–373) 20.239 9E-86
s-VLDL-FC 6,580 114 (103–144) 20.301 9E-137
vs-VLDL-P 31.3 6,580 0.037 (0.033–0.046) 20.079 2E-10
vs-VLDL-PL 6,580 154 (133–192) 0.049 8E-05
vs-VLDL-TG 6,580 130 (121–167) 20.277 6E-116
IDL-P 28.6 6,580 0.098 (0.086–0.118) 0.041 0.0009
IDL-PL 6,580 315 (274–379) 0.072 5E-09
IDL-TG 6,580 128 (115–161) 20.115 1E-20
IDL-C 6,580 792 (689–938) 0.082 3E-11
IDL-FC 6,579 218 (184–264) 0.171 7E-44
l-LDL-P 25.5 6,580 0.17 (0.15–0.21) 20.002 0.856
l-LDL-PL 6,580 375 (335–439) 20.003 0.783
l-LDL-C 6,580 1,112 (960–1334) 0.015 0.235
l-LDL-FC 6,580 292 (252–346) 0.086 3E-12
l-LDL-CE 6,580 819 (705–986) 20.009 0.470
m-LDL-P 23.0 6,580 0.15 (0.13–0.18) 20.051 4E-05
m-LDL-PL 6,580 246 (224–285) 20.089 4E-13
m-LDL-C 6,580 670 (572–813) 20.030 0.015
m-LDL-CE 6,580 493 (419–607) 20.034 0.006
s-LDL-P 18.7 6,580 0.17 (0.15–0.20) 20.062 6E-07
s-LDL-C 6,580 395 (340–485) 20.018 0.145
vl-HDL-P 14.3 6,439 0.27 (0.15–0.32) 0.353 5E-187
vl-HDL-PL 6,376 152 (74–176) 0.360 9E-194
vl-HDL-TG 6,577 11.5 (9.7–15.1) 0.045 0.0003
vl-HDL-C 6,441 188 (121–229) 0.292 5E-126
vl-HDL-FC 6,432 46.2 (28.0–55.1) 0.312 2E-144
vl-HDL-CE 6,462 142 (94–173) 0.301 1E-134
l-HDL-P 12.1 6,571 0.81 (0.47–0.98) 0.412 1E-266
l-HDL-PL 6,562 301 (179–372) 0.401 1E-250
l-HDL-C 6,571 321 (175–382) 0.412 6E-266
l-HDL-FC 6,334 63.8 (27.0–75.0) 0.396 3E-235
l-HDL-CE 6,576 261 (150–309) 0.389 8E-235
m-HDL-P 10.9 6,580 1.62 (1.42–1.88) 0.114 3E-20
m-HDL-PL 6,580 395 (345–461) 0.140 9E-30
m-HDL-C 6,579 458 (384–525) 0.163 3E-40
m-HDL-FC 6,579 83.9 (69.5–99.1) 0.212 3E-67
m-HDL-CE 6,579 378 (317–430) 0.146 1E-32
s-HDL-P 8.7 6,580 4.66 (4.44–4.98) 20.166 1E-41
s-HDL-TG 6,572 44.8 (39.9–59.7) 20.321 4E-156
IQR, interquartile range; P, particle concentration.
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1610 DIABETES, VOL. 60, MAY 2011 diabetes.diabetesjournals.orgFIG. 1. Signiﬁcances (A) and effect sizes (B) of associations between 34 SNP and 60 lipoprotein traits in nondiabetic men. P values (presented
as 2log10) were calculated by linear regression adjusted for age, BMI, statin treatment, and smoking, using log-transformed variables. Un-
standardized effect sizes (presented as percentage from the mean) per type 2 diabetes/hyperglycemia risk allele were calculated from the same
model, using untransformed variables. P, particle concentration.
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from 8.1 3 10
25 to 0.006) and their components and low
concentration of vl-HDL (P = 0.038) and l-HDL (P =0 . 0 0 4 )
particles and their components (Fig. 2C, Supplementary
Table 4). The association with s-VLDL was signiﬁcant when
using FDR correction (PFDR = 0.030), as well as associa-
tions with components of m-VLDL (FC, PFDR =0 . 0 5 ) ,s -
VLDL (PL, PFDR = 0.045; TG, PFDR = 0.020), and vs-VLDL
(TG, PFDR = 0.016). These associations, however, dis-
appeared after additional adjustment for TGs.
FIG. 2. Effects of GCKR rs780094 (A), FADS1 rs174550 (B), NOTCH2 rs10923931 (C), and HNF1B rs7501939 (D) on lipoprotein subclasses and
their components in nondiabetic men. Bars represent percentage change to the mean of the trait per copy of a minor allele and were calculated by
linear regression adjusted for age, BMI, statin treatment, and smoking. *Signiﬁcant association after Bonferroni correction (P < 2.3 3 10
25)o r
FDR correction for multiple testing (PFDR < 0.05).
cNominally signiﬁcant associations (P < 0.05). P, particle concentration.
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nominally associated with particle concentrations and
components of most of the lipoprotein subclasses (Fig. 2D,
Supplementary Table 5). The type 2 diabetes risk (minor)
A allele was nominally associated with low concentrations
of l- to vs-VLDL, IDL, and LDL (all subclasses), and with
high concentrations of vl-HDL particles (P = 4.1 3 10
24 to
0.039). Signiﬁcant associations (using FDR correction) were
observed for concentration of s-HDL particles (PFDR =
0.017), the TG component of vs-VLDL (PFDR = 0.044), and
the PL component of m-LDL (PFDR = 0.030), with effect
sizes of a 1–3% decrease per A allele. The associations were
weakened by additional adjustment for TGs.
The results for GCKR rs780094, FADS1 rs174550,
NOTCH2 rs10923931, and HNF1B rs7501939 remained
essentially similar when statin users (n = 1,545) were ex-
cluded (data not shown).
The quantile-quantile (Q-Q) plot of the association
results between the 34 SNPs and the 60 lipoprotein traits
(observed 2log10 P values against theoretic expected 2
log10 P values) shows a large deviation from the null hy-
pothesis of no association, strongly suggesting that the
deviating results are true signiﬁcant associations (Fig. 3).
After the P values of two most signiﬁcant SNPs (in GCKR
and FADS1) were excluded from the analyses, the Q-Q
plot still deviated from the null hypothesis. This suggests
that some of the remaining associations could be true sig-
niﬁcant associations. However, after P values of NOTCH2
and HNF1B SNPs were also excluded, the deviation from
the null hypothesis was largely decreased; therefore, the
nominally signiﬁcant associations in the remaining SNPs
might be false ﬁndings, such as associations of CDC123
rs12779790 with vl- and l-HDL particles, DGKB rs2191349
with vl-HDL particles, FTO rs9939609 with l- and m-LDL and
vl-HDL, JAZF1 rs864745 with l- to s-VLDL and all LDL
particles, KCNJ11 rs5219 with m- and s-HDL, and PROX1
rs340874 with CM/lar-VLDL and vl- to s-VLDL particles, and
with vl- and l-HDL.
The GRS calculated using all 34 SNPs did not show
signiﬁcant associations with concentrations of any of the
particles, and the same was observed for GRST2D, which
included type 2 diabetes risk SNPs or GRSGLU, including
hyperglycemia SNPs (Supplementary Table 6). Nominally
signiﬁcant associations of GRSGLU with vl-HDL (P = 0.047)
and l-HDL (P = 0.012) particle concentrations disappeared
after GCKR and FADS1 SNPs were excluded from the
calculations. This suggests that the associations of in-
dividual SNPs with the lipoprotein traits as described are
speciﬁc for these traits and are not an indication of sys-
tematic effects of type 2 diabetes/hyperglycemia risk SNPs
on lipoprotein metabolism.
All lipoprotein traits, with the exception of l-LDL par-
ticles, were signiﬁcantly correlated with Matsuda ISI. The
strongest correlations were observed for CM/lar-VLDL and
the vl- to s-VLDL subclasses, particularly with their TG
components (r=20.41 to 20.45), and with l-HDL particles
and all their components (r = 20.39 to 20.41; Table 1). Of
four SNPs signiﬁcantly associated with lipoprotein traits,
GCKR rs780094 and NOTCH2 rs10923931 showed nomi-
nally signiﬁcant associations with Matsuda ISI (P =0 . 0 0 1
and 0.012, respectively, Supplementary Table 7). This could
suggest that the associations between these two SNPs and
lipoproteins are mediated through their effects on insulin
sensitivity. Additional adjustment for Matsuda ISI indeed
decreased the effects of NOTCH2 rs10923931 on lipo-
proteins, but no such effect was observed for other SNPs.
However, the effect of SNPs on lipoproteins was very small:
GCKR and FADS1 SNPs explained a #1.3% variance in
their most associated lipoprotein traits compared with the
effect of Matsuda ISI, which explained a 12–19% variance
i nt h es a m et r a i t s .
DISCUSSION
This is the ﬁrst large population–based study where the
effects of 34 conﬁrmed–risk SNPs for hyperglycemia or
type 2 diabetes on lipoprotein subclasses and their com-
position have been systematically investigated. We found
that 4 of the 34 tested SNPs, in GCKR, FADS1, HNF1B,
and NOTCH2 genes, were signiﬁcantly associated with
lipoprotein traits after correction for multiple testing. This
indicates that there could be some overlap between the
genes affecting both glucose and lipoprotein metabolism.
Associations of GCKR rs780094 with lipoprotein sub-
classes and composition. The most statistically signiﬁ-
cant ﬁnding was the association of the hyperglycemia/
type 2 diabetes–risk C allele of the intronic SNP rs780094
of GCKR with low concentrations of all subclasses of
VLDL particles (effect sizes 10–2% per allele for CM/lar-VLDL
and vl- to s-VLDL) as well as with the diameter of VLDL
particles. Only one previous study has examined the effects
of GCKR on lipoprotein fractions, reporting an associa-
tion (P , 5 3 10
28) of rs1260326 at the GCKR locus (in
linkage disequilibrium with rs780094, r
2 =0 . 8 9a c c o r d i n gt o
HapMap CEU) with large and medium-size VLDL particles
and mean particle size (22), which is in agreement with our
ﬁndings. Furthermore, the C allele of rs780094 was signiﬁ-
cantly associated in our study with a low concentration of
s-LDL particles and s-HDL particles, besides nominal asso-
ciations with IDL and other subclasses of LDL and HDL
FIG. 3. Quantile-quantile (Q-Q) plot of the association results between
34 hyperglycemia and type 2 diabetes risk SNPs and 60 lipoprotein
traits (observed 2log10 P values against theoretical expected 2log10 P
values). The diagonal black line represents theoretical expected values
and the gray dashed lines their 95% CI. Blue dots, all P values; red dots,
P values for two leading SNPs (GCKR rs780094 and FADS1 rs174550)
excluded; green dots, P values for four SNPs showing signiﬁcant (PFDR <
0.05) associations (in GCKR, FADS1, HNF1B, NOTCH2)e x c l u d e d .
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ciations of rs780094 with s-LDL particles and s-HDL par-
ticles (22).
In addition, we observed a tendency to a stronger as-
sociation of the C allele with the TG components of most
of the lipoprotein subclasses than with other components.
Previous studies and GWAS, applying only standard mea-
surements of lipoprotein levels, have consistently shown
that the C allele of rs780094 was associated with low TG
levels (23–25). In the ﬁrst GWAS performed by the Di-
abetes Genetics Initiative consortium, rs780094 explained
1% of the residual variance in TG levels (23). Similarly, the
missense variant rs1260326 (Leu446Pro), which could be
responsible for the associations of rs780094 (26), has been
associated with TG levels in several studies (26–30). Our
study suggests that the association between GCKR and TG
is attributable to changes in VLDL particle concentration,
especially in the largest TG-rich subclasses. Additional
adjustment for serum TG levels abolished all associations
of the SNP with particles and their components, suggesting
that the observed effects of rs780094 on IDL, LDL, and
HDL particles could be secondary to its effects on TG/
VLDL metabolism rather than independent effects.
A previous study proposed that large TG-rich VLDL
particles, secreted by the liver preferentially in hyper-
triglyceridemic conditions, are metabolized into small LDL
particles (31), which could explain the stronger associa-
tion of rs780094 with s-LDL particles in our study. The
inverse relationship between TG and HDL levels is well
documented (32) and is at least partly explained by in-
creased catabolism of TG-enriched HDL particles (33).
The main biologic function of the glucokinase regulatory
protein is to inhibit the effects of glucokinase on glycogen
synthesis and glycolysis in the liver (34). SNPs at the
GCKR locus have been associated with fasting glycemia
(9,29), risk of type 2 diabetes (25,29), insulin resistance
(25,29,35), and increased hepatic glucose production (26).
Our study also conﬁrmed the association of the C allele of
rs780094 with decreased insulin sensitivity (Matsuda ISI).
However, it did not seem to account for the changes in li-
poprotein particle concentrations, because additional ad-
justment for Matsuda ISI did not attenuate the associations
between rs780094 and lipoproteins. Moreover, the effects of
rs780094 on insulin resistance and TG levels were in op-
posite directions. A recent article reporting that Leu446Pro
indirectly increases GK activity proposed that the increased
glycolytic ﬂux leads to the elevation of malonyl-CoA,
a substrate for de novo lipogenesis, which could explain the
opposite effects of the SNP on glucose and TG levels (36).
Associations of FADS1 rs174550 with lipoprotein sub-
classes and composition. The glucose-increasing (major)
T allele of the intronic SNP rs174550 in the FADS1 gene was
signiﬁcantly associated with high concentrations of vl- and
l-HDL particles and all of their components, as well as with
HDL particle diameter. Nominally signiﬁcant associations
were found with all VLDL subclasses and IDL particles.
A previous study (22) found an association of two other
SNPs at the FADS1-2-3 gene cluster with medium HDL
(rs174537) and large HDL particles (rs102275), and one
SNP with large LDL particles (rs1535). Moreover, four
recent GWAS (28,30,37,38) reported associations of the
FADS1-2-3 SNPs with HDL cholesterol, total cholesterol,
LDL cholesterol, and TG. Our ﬁndings suggest that rs174550
may primarily affect vl- and l-HDL particles because the
associations persisted after additional adjustment for serum
TG levels. We did not observe any associations of rs174550
with LDL subclasses.
FADS1 encodes the fatty acid desaturase d-5 (D5D),
which plays a crucial role in desaturation and elongation
of polyunsaturated fatty acids (PUFA). Several SNPs at
the FADS1 locus have been previously associated with
PUFA concentrations in serum and tissue phospholipids
(39,40). Association of the FADS1 locus (rs174537) with
serum PUFA levels was been conﬁr m e db yaG W A Si nt h e
Invecchiare in Chianti (InCHIANTI) study (41). The PL
component of vl-HDL particles was one of the most strongly
inﬂuenced traits by rs174550 in our study. FADS1,b y
its effects on PUFA metabolism, may inﬂuence the com-
position and properties of phospholipids of HDL particles
(forming ;20% of a particle), which could further affect the
biogenesis, maturation, and catabolism of HDL. In support
for this notion, FADS1 (rs174548) has also been shown to
affect serum levels of phosphatidylcholine (42), which is
the major phospholipid in HDL particles and is important in
the metabolism of HDL particles (43). Furthermore, dietary
PUFAs have been shown to inﬂuence lipoprotein levels,
mainly HDL and LDL cholesterol (44), and variants affecting
biosynthesis of PUFAs could have similar effects.
The T allele of rs174550 has been previously associated
with increased fasting glucose levels in a GWAS by the
Meta-Analyses of Glucose and Insulin-related traits Con-
sortium (MAGIC) (9). However, similar to our observation
for the GCKR locus, the glucose-increasing allele was as-
sociated with high HDL and nominally with low VLDL
concentrations. This may suggest that the effects of FADS1
variants on lipoproteins and glucose levels are mediated by
different mechanisms. PUFAs have an ability to potentiate
insulin secretion (45), which could be one of the mecha-
nisms by which FADS1 variants modulate insulin secretion
(35) and fasting glucose levels (9).
Associations of HNF1B rs7501939 and NOTCH2
10923931 with lipoprotein subclasses and composition.
HNF1B rs7501939 and NOTCH2 10923931 showed mostly
nominally signiﬁcant associations with several lipoprotein
traits, some of them being statistically signiﬁcant using the
less conservative FDR correction for multiple testing. The
type 2 diabetes risk allele of the intronic SNP rs7501939 in
HNF1B was associated with high particle concentrations
of all VLDL subclasses (signiﬁcantly with s-VLDL) and
s-LDL particles and low concentrations of vl- and l-HDL
particles. Although there are no studies on the effect of
common SNPs of HNF1B on lipid levels, patients with
maturity-onset diabetes of the young type 5 caused by
mutations at the HNF1B locus exhibit dyslipidemia char-
acterized by hypertriglyceridemia and low HDL choles-
terol levels (46).
The type 2 diabetes risk allele of the intronic SNP
rs10923931 in NOTCH2 was nominally associated with low
particle concentrations of all VLDL, IDL, and LDL sub-
classes, high concentrations of vl-HDL particles, and sig-
niﬁcantly with low concentration of s-HDL particles. The
same allele was nominally associated with higher insulin
sensitivity (Matsuda ISI), and an additional adjustment
for Matsuda ISI attenuated the associations between
rs10923931 and lipoproteins, indicating that these effects
could be at least partly related. Associations of NOTCH2
variants with lipid levels or insulin sensitivity have not
been previously reported. The mechanisms behind the
observed associations remain to be elucidated.
JAZF1, CDC123, PROX1, KCNJ11, FTO, and DGKB loci
were nominally associated with several lipoprotein traits
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previously found to affect lipid levels (47).
GRS calculated using all 34 SNPs, or type 2 diabetes SNPs
and hyperglycemia SNPs separately, was not signiﬁcantly
associated with any of the lipoprotein subclasses. This sug-
gests that there is no major overlap between the genetic basis
of type 2 diabetes/hyperglycemia and lipoprotein metabolism.
Furthermore, although insulin resistance is a major patho-
physiologic link between hyperglycemia and dyslipidemia,
our results do not give evidence for a role of the examined
SNPs in this association. PPARG, as the main candidate gene
for insulin resistance, was not signiﬁcantly associated with
any of the lipoprotein traits. In contrast, the C allele of
rs780094 of GCKR was associated with decreased insulin
sensitivity and low concentrations of VLDL particles, sug-
gesting that the effects of the C allele on glucose and lipid
metabolism could be independently regulated. The FADS1
and HNF1B SNPs were not associated with insulin resistance
in our study. Associations of NOTCH2 with lipoproteins
could be related to its possible effect on insulin sensitivity.
A limitation of our study is that only Finnish men were
included, and therefore, we do not know whether our re-
sults are applicable to women and to different ethnic or
racial groups. We had only a modest statistical power to
demonstrate statistically signiﬁcant associations with CM,
largest to medium VLDL, and HDL particles.
In conclusion, our large population-based study shows
that from the 34 loci associated with hyperglycemia or type
2 diabetes only GCKR, FADS1, HNF1B,a n dNOTCH2 were
signiﬁcantly associated with several lipoprotein traits. The
effects of GCKR were predominantly on concentrations of
VLDL particles, and FADS1 seems to mainly affect con-
centrations of vl- and l-HDL particles. Our ﬁndings indicate
that only a limited number of risk loci for hyperglycemia or
type 2 diabetes affect signiﬁcantly lipoprotein metabolism.
ACKNOWLEDGMENTS
This work was supported by the Academy of Finland
(M.L., SALVE program to M.A.K.), the Finnish Diabetes
Research Foundation (M.L.), the Finnish Cardiovascular
Research Foundation (M.L., M.A.-K.), the Jenny and Antti
Wihuri Foundation (A.J.K.), and an EVO grant from the
Kuopio University Hospital (5263), DK062370 to M.B., and
1Z01 HG000024 to F.S.C.
No potential conﬂicts of interest relevant to this article
were reported.
A.S. wrote the manuscript and researched data. J.P.
researched data and reviewed and edited the manuscript.
P.S. conceived and designed the experiments, performed
the experiments, analyzed the data, and reviewed and edited
the manuscript. A.J.K. analyzed the data, contributed anal-
ysis tools, and reviewed and edited the manuscript. L.L.B.
and M.A.M. performed experiments and reviewed and
edited the manuscript. F.S.C. designed the experiments
and reviewed and edited the manuscript. A.U.J. contributed
analysis tools and reviewed and edited the manuscript.
M.L.B. contributed to discussion and reviewed and edited
the manuscript. J.K. designed the study and reviewed the
manuscript. M.A.-K. conceived and designed the experi-
ments, analyzed the data, and reviewed and edited the
manuscript. M.L. designed the study, contributed to discus-
sion, and reviewed and edited the manuscript.
REFERENCES
1. Zhang L, Qiao Q, Tuomilehto J, et al.; DECODE Study Group. Blood lipid
levels in relation to glucose status in European men and women without
a prior history of diabetes: the DECODE Study. Diabetes Res Clin Pract
2008;82:364–377
2. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract
Endocrinol Metab 2009;5:150–159
3. Tirosh A, Shai I, Bitzur R, et al. Changes in triglyceride levels over time and
risk of type 2 diabetes in young men. Diabetes Care 2008;31:2032–2037
4. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino RB Sr.
Prediction of incident diabetes mellitus in middle-aged adults: the Fra-
mingham Offspring Study. Arch Intern Med 2007;167:1068–1074
5. Ley SH, Harris SB, Connelly PW, et al. Association of apolipoprotein B
with incident type 2 diabetes in an aboriginal Canadian population. Clin
Chem 2010;56:666–670
6. Mykkänen L, Kuusisto J, Pyörälä K, Laakso M. Cardiovascular disease risk
factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in
elderly subjects. Diabetologia 1993;36:553–559
7. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and
cardiovascular disease. Clin Biochem 2009;42:1331–1346
8. McCarthy MI, Zeggini E. Genome-wide association studies in type 2 di-
abetes. Curr Diab Rep 2009;9:164–171
9. Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated
in fasting glucose homeostasis and their impact on type 2 diabetes risk.
Nat Genet 2010;42:105–116
10. Saxena R, Hivert MF, Langenberg C, et al. Genetic variation in GIPR in-
ﬂuences the glucose and insulin responses to an oral glucose challenge.
Nat Genet 2010;42:142–148
11. Stancáková A, Javorský M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M.
Changes in insulin sensitivity and insulin release in relation to glycemia and
glucose tolerance in 6,414 Finnish men. Diabetes 2009;58:1212–1221
12. World Health Organization, Department of Noncommunicable Disease
Surveillance. Deﬁnition, Diagnosis and Classiﬁcation of Diabetes and its
Complications: Report of a WHO Consultation. Part 1: Diagnosis and
Classiﬁcation of Diabetes. Geneva, Switzerland, World Health Org., 1999,
p. 1–49
13. Ala-Korpela M.
1H NMR spectroscopy of human blood plasma. Prog Nucl
Magn Reson Spectrosc 1995;27:475–554
14. Ala-Korpela M. Critical evaluation of
1H NMR metabonomics of serum as
a methodology for disease risk assessment and diagnostics. Clin Chem Lab
Med 2008;46:27–42
15. Ala-Korpela M, Soininen P, Savolainen MJ. Letter by Ala-Korpela et al re-
garding article, “Lipoprotein particle proﬁles by nuclear magnetic reso-
nance compared with standard lipids and apolipoproteins in predicting
incident cardiovascular disease in women”. Circulation 2009;120:e149;
author reply e150
16. Soininen P, Kangas AJ, Würtz P, et al. High-throughput serum NMR me-
tabonomics for cost-effective holistic studies on systemic metabolism.
Analyst (Lond) 2009;134:1781–1785
17. Vehtari A, Mäkinen VP, Soininen P, et al. A novel Bayesian approach to
quantify clinical variables and to determine their spectroscopic counterparts
in
1H NMR metabonomic data. BMC Bioinformatics 2007;8(Suppl. 2):S8
18. Okazaki M, Usui S, Ishigami M, et al. Identiﬁcation of unique lipoprotein
subclasses for visceral obesity by component analysis of cholesterol pro-
ﬁle in high-performance liquid chromatography. Arterioscler Thromb Vasc
Biol 2005;25:578–584
19. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple
testing under dependency. Ann Stat 2001;29:1165–1188
20. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral
glucose tolerance testing: comparison with the euglycemic insulin clamp.
Diabetes Care 1999;22:1462–1470
21. Warnes G, Duffy D, Man M, Qui W, Ross L. GeneticsDesign: functions for
designing genetics studies. Bioconducter, R package version 1.16.0, 2010
22. Chasman DI, Paré G, Mora S, et al. Forty-three loci associated with plasma
lipoprotein size, concentration, and cholesterol content in genome-wide
analysis. PLoS Genet 2009;5:e1000730
23. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund
University, and Novartis Institutes of BioMedical Research; Saxena R,
Voight BF, Lyssenko V, et al. Genome-wide association analysis identiﬁes
loci for type 2 diabetes and triglyceride levels. Science 2007;316:1331–1336
24. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with
blood low-density lipoprotein cholesterol, high-density lipoprotein cho-
lesterol or triglycerides in humans. Nat Genet 2008;40:189–197
25. Sparsø T, Andersen G, Nielsen T, et al. The GCKR rs780094 polymorphism
is associated with elevated fasting serum triacylglycerol, reduced fasting
and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Dia-
betologia 2008;51:70–75
26. Orho-Melander M, Melander O, Guiducci C, et al. Common missense var-
iant in the glucokinase regulatory protein gene is associated with increased
STAN CÁKOVÁ AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, MAY 2011 1615plasma triglyceride and C-reactive protein but lower fasting glucose con-
centrations. Diabetes 2008;57:3112–3121
27. Willer CJ, Sanna S, Jackson AU, et al. Newly identiﬁed loci that inﬂuence
lipid concentrations and risk of coronary artery disease. Nat Genet 2008;
40:161–169
28. Sabatti C, Service SK, Hartikainen AL, et al. Genome-wide association
analysis of metabolic traits in a birth cohort from a founder population.
Nat Genet 2009;41:35–46
29. Vaxillaire M, Cavalcanti-Proença C, Dechaume A, et al.; DESIR Study
Group. The common P446L polymorphism in GCKR inversely modulates
fasting glucose and triglyceride levels and reduces type 2 diabetes risk
in the DESIR prospective general French population. Diabetes 2008;57:
2253–2257
30. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and
population relevance of 95 loci for blood lipids. Nature 2010;466:707–
713
31. Tan CE, Foster L, Caslake MJ, et al. Relations between plasma lipids and
postheparin plasma lipases and VLDL and LDL subfraction patterns in
normolipemic men and women. Arterioscler Thromb Vasc Biol 1995;15:
1839–1848
32. Lamarche B, Rashid S, Lewis GF. HDL metabolism in hypertriglyceridemic
states: an overview. Clin Chim Acta 1999;286:145–161
33. Lamarche B, Uffelman KD, Carpentier A, et al. Triglyceride enrichment of
HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men.
J Clin Invest 1999;103:1191–1199
34. de la Iglesia N, Mukhtar M, Seoane J, Guinovart JJ, Agius L. The role of the
regulatory protein of glucokinase in the glucose sensory mechanism of the
hepatocyte. J Biol Chem 2000;275:10597–10603
35. Ingelsson E, Langenberg C, Hivert MF, et al.; MAGIC investigators. De-
tailed physiologic characterization reveals diverse mechanisms for novel
genetic Loci regulating glucose and insulin metabolism in humans. Di-
abetes 2010;59:1266–1275
36. Beer NL, Tribble ND, McCulloch LJ, et al. The P446L variant in GCKR
associated with fasting plasma glucose and triglyceride levels exerts its
effect through increased glucokinase activity in liver. Hum Mol Genet
2009;18:4081–4088
37. Aulchenko YS, Ripatti S, Lindqvist I, et al.; ENGAGE Consortium. Loci
inﬂuencing lipid levels and coronary heart disease risk in 16 European
population cohorts. Nat Genet 2009;41:47–55
38. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci
contribute to polygenic dyslipidemia. Nat Genet 2009;41:56–65
39. Schaeffer L, Gohlke H, Müller M, et al. Common genetic variants of the
FADS1 FADS2 gene cluster and their reconstructed haplotypes are asso-
ciated with the fatty acid composition in phospholipids. Hum Mol Genet
2006;15:1745–1756
40. Lattka E, Illig T, Koletzko B, Heinrich J. Genetic variants of the FADS1
FADS2 gene cluster as related to essential fatty acid metabolism. Curr
Opin Lipidol 2010;21:64–69
41. Tanaka T, Shen J, Abecasis GR, et al. Genome-wide association study of
plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet
2009;5:e1000338
42. Gieger C, Geistlinger L, Altmaier E, et al. Genetics meets metabolomics:
a genome-wide association study of metabolite proﬁles in human serum.
PLoS Genet 2008;4:e1000282
43. Kadowaki H, Patton GM, Robins SJ. Effect of phosphatidylcholine mo-
lecular species on the uptake of HDL triglycerides and cholesteryl esters
by the liver. J Lipid Res 1993;34:180–189
44. Wanders AJ, Brouwer IA, Siebelink E, Katan MB. Effect of a high intake of
conjugated linoleic acid on lipoprotein levels in healthy human subjects.
PLoS ONE 2010;5:e9000
45. Opara EC, Garﬁnkel M, Hubbard VS, Burch WM, Akwari OE. Effect of fatty
acids on insulin release: role of chain length and degree of unsaturation.
Am J Physiol 1994;266:E635–E639
46. Pearson ER, Badman MK, Lockwood CR, et al. Contrasting diabetes
phenotypes associated with hepatocyte nuclear factor-1alpha and -1beta
mutations. Diabetes Care 2004;27:1102–1107
47. Doney AS, Dannfald J, Kimber CH, et al. The FTO gene is associated with
an atherogenic lipid proﬁle and myocardial infarction in patients with type
2 diabetes: a Genetics of Diabetes Audit and Research Study in Tayside
Scotland (Go-DARTS) study. Circ Cardiovasc Genet 2009;2:255–259
TYPE 2 DIABETES/HYPERGLYCEMIA SNPs AND LIPOPROTEINS
1616 DIABETES, VOL. 60, MAY 2011 diabetes.diabetesjournals.org